DiscoverSmart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
Claim Ownership

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Author: David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist

Subscribed: 36Played: 1,487
Share
© 2026 Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Description

The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.


Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials.


Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.


This podcast is for you if:


  • You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership


  • You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness


  • You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny


  • You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources


What you will learn:


CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma.


Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.


New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.


Next Steps:


Get the 5-day CMC email course: https://smartbiotechscientist.com/#cmc


Visit the website: https://smartbiotechscientist.com


Email us: [email protected]

301 Episodes
Reverse
300: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 2

300: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 2

2026-10-2922:17

Is your process model gathering dust while real-world decisions march on without it? Many technically strong digital tools—no matter how powerful—end up sidelined in bioprocess development. Why is that, and what does it actually take for digital modeling to earn its place at the lab bench? In this episode, David Brühlmann sits down with Moritz von Stosch of HINA Bioventures, a scientist-turned-investor who’s navigated both the technology provider and pharma end-user sides. Moritz von Stosch b...
299: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 1

299: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 1

2026-10-2721:24

Are you frustrated with reinventing the wheel every time a new molecule enters bioprocess development? Is there a better way to harness data and modeling to accelerate breakthroughs in biotech? The bioprocessing industry is constantly searching for ways to streamline development, reduce costs, and speed new therapies to market—yet leveraging existing knowledge remains a significant challenge. In this episode, David Brühlmann welcomes Moritz von Stosch, partner at HINA Bioventures and a pionee...
298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

2026-10-2216:23

The entire public record of antibody affinity data comes to about half a million measurements, and by David Younger's estimate, upwards of 75% of it is AlphaSeq data from his own company's publications. His conclusion is that no single company can close the gap alone. So he is asking pharma and AI labs to pay for an experiment and share every result with the other members. In Part 2 of this two-part conversation, David Brühlmann talks with Younger, founding CEO of A-Alpha Bio, whose AlphaSeq ...
297: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 1

297: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 1

2026-10-2028:05

The Protein Data Bank holds about 10,000 antibody-antigen structures and grows by roughly 1,000 a year. David Younger's scaling work suggests that generalizable de novo antibody design needs hundreds of thousands to millions. At that pace, even 200,000 structures is nearly two centuries away. In this episode, David Brühlmann hosts David Younger, founding CEO of A-Alpha Bio and the mind behind the AlphaSeq platform. Trained at the intersection of synthetic biology and computational protein eng...
296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

2026-10-1520:39

Cardiovascular disease has long been managed by slowing its relentless progression. But Matthew O'Connor, CEO of Scientific Affairs at Cyclarity Therapeutics, is betting on an outright paradigm shift: treating atherosclerotic plaque with therapies designed to actively reverse disease, not simply manage symptoms or risk. In this episode, David Brühlmann explores the strategy, regulatory journey, and manufacturing realities behind Cyclarity's unconventional cyclodextrin-based approach—a molecul...
loading
Comments 
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States